Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMA7PEW)

• Drug Name: Verapamil Drug Info
• Synonyms: Arpamyl; Calan; Calcan; Cordilox; Dexverapamil; Dilacoran; Drosteakard; Iproveratril; Isoptimo; Isoptin; Isotopin; Vasolan; Veracim; Verapamilo; Verapamilum; Veraptin; Verexamil; Bosoptin (TN); Calan (TN); D-365; Isoptin (TN); Verapamilo [INN-Spanish]; Verapamilum [INN-Latin]; Verelan (TN); CP-16533-1; Covera-HS (TN); Verapamil (USAN/INN); Verapamil [USAN:BAN:INN]; Verapamil [USAN:INN:BAN]; Alpha-((N-Methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Alpha-Isopropyl-alpha-((N-methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Alpha-(3-((2-(3,4-Dimethoxyphenyl)ethyl)-methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile; (+-)-Verapamil; (+/-)-VERAPAMIL; (1)-3-(3,4-Dimethoxyphenyl)-6-((5,6-dimethoxyphenethyl)methylamino)hexane-3-carbonitrile; 2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-(1-methylethyl) pentanenitrile; 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile; 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile; 5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; Verapamil (Na-Ca chanel blocker)

Indication

Disease Entry	ICD 11	Status	REF
Angina pectoris	BA40	Approved	[1]
Atrial fibrillation	BC81.3	Approved	[1]
Classic phenylketonuria		Approved	[1]
Hypertension	BA00-BA04	Approved	[2]
Malignant essential hypertension	BA00	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2/3	[3]

• Therapeutic Class: Analgesics
• Cross-matching ID:
  PubChem CID: 2520
  ChEBI ID: CHEMBL6966
  CAS Number: CAS 52-53-9
  TTD Drug ID: DMA7PEW
  VARIDT Drug ID: DR00264
  INTEDE Drug ID: DR1681
  ACDINA Drug ID: D00726

Molecule-Related Drug Atlas

Drug(s) Targeting Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethosuximide	DMDZ9LT	Epilepsy	8A60-8A68	Approved	[27]
Trimethadione	DM0Q8MZ	Absence epilepsy		Approved	[28]
Paramethadione	DMR5ZUP	Absence epilepsy		Approved	[28]
Methsuximide	DM6L5VO	Absence epilepsy		Approved	[29]
Penfluridol	DMG1DTE	Schizophrenia	6A20	Approved	[30]
PD-200390	DMPW28M	Insomnia	7A00-7A0Z	Phase 2	[31]
NGD 94-1	DMM1Y8F	Schizophrenia	6A20	Phase 1	[30]
ML218	DM3D21X	Discovery agent	N.A.	Investigative	[32]
KYS-05001	DM3MID9	Discovery agent	N.A.	Investigative	[33]
KYS-05077	DMHW40F	Discovery agent	N.A.	Investigative	[34]

Drug(s) Targeting HUMAN two pore channel subtype 2 (TPC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[5]

Drug(s) Transported By Multidrug resistance-associated protein 1 (ABCC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[35]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[36]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[37]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[38]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[39]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[40]
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[41]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[42]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[43]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[10]

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[10]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[44]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[45]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[46]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[45]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[45]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[47]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[45]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[48]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[49]

Drug(s) Transported By Organic cation transporter 1 (SLC22A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[50]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[51]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[52]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[53]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[10]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[54]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[55]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[56]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[57]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[10]

Drug(s) Transported By Multidrug resistance protein 3 (ABCB4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Digoxin	DMQCTIH	Arrhythmia	BC9Z	Approved	[6]
Vinblastine	DM5TVS3	Advanced cancer	2A00-2F9Z	Approved	[6]
SILODOSIN	DMJSBT6	Benign prostatic hyperplasia	GA90	Approved	[58]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[6]

Drug(s) Transported By Organic cation/carnitine transporter 2 (SLC22A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[59]
Entecavir	DM7VTQO	Hepatitis B virus infection	1E51.0	Approved	[60]
Levacecarnine hci	DMJBOCR	Cognitive impairment	6D71	Approved	[61]
Amphetamine	DMSZQAK	Attention deficit hyperactivity disorder	6A05.Z	Approved	[62]
Potassium Chloride	DMMTAJC	Hypokalemia	5C77	Approved	[63]
Tiotropium	DMFDC0Q	Chronic obstructive pulmonary disease	CA22	Approved	[64]
Ipratropium	DMFQ320	Obstructive lung disease	CA22.Z	Approved	[64]
Mepyramine	DMB4SFH	Allergic rhinitis	CA08.0	Approved	[65]
Acetylcarnitine	DM4UE3K	Chronic fatigue syndrome	8E49	Phase 4	[66]
acetyl-L-carnitine	DM74HGJ	Discovery agent	N.A.	Investigative	[59]
Levacecarnine hci	DMJBOCR	Cognitive impairment	6D71	Approved	[168]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[169]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[170]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[171]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[172]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[173]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[174]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[175]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[176]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[177]

Drug(s) Transported By Organic cation/carnitine transporter 1 (SLC22A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[7]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[67]
Levacecarnine hci	DMJBOCR	Cognitive impairment	6D71	Approved	[68]
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[69]
Ipratropium	DMFQ320	Obstructive lung disease	CA22.Z	Approved	[64]
[14C]TEA	DM6SFYH	Discovery agent	N.A.	Investigative	[70]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[71]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[72]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[73]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[74]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[75]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[76]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[77]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[78]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[72]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[79]

Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[80]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[81]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[82]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[83]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[84]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[85]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[77]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[86]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[87]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[88]

Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[89]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[90]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[91]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[92]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[93]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[94]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[95]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[96]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[92]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[97]

Drug(s) Metabolized By Cytochrome P450 2E1 (CYP2E1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[98]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[99]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[100]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[101]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[102]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[86]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[103]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[104]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[105]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[106]

Drug(s) Metabolized By Cytochrome P450 3A7 (CYP3A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[107]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[92]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[92]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[92]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[13]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[92]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[92]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[92]
Metronidazole	DMTIVEN	Abscess		Approved	[108]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[109]

Drug(s) Metabolized By Cytochrome P450 2C18 (CYP2C18)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[110]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[111]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[112]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[113]
Methadone	DMTW6IU	Advanced cancer	2A00-2F9Z	Approved	[114]
Dapsone	DM4LT8A	Acne vulgaris	ED80	Approved	[115]
Lidocaine	DML4ZOT	Anaesthesia	9A78.6	Approved	[13]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[116]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[117]

Drug(s) Metabolized By Cytochrome P450 2C8 (CYP2C8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[80]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[118]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[118]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[13]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[119]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[120]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[118]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[121]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[111]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[122]

Drug(s) Metabolized By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[123]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[124]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[125]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[13]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[126]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[13]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[127]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[128]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[129]
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[130]

Drug(s) Metabolized By Cytochrome P450 2B6 (CYP2B6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[131]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[132]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[125]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[133]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[134]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[135]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[136]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[137]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[138]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[13]

Drug(s) Metabolized By Mephenytoin 4-hydroxylase (CYP2C19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[139]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[123]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[140]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[141]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[13]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[110]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[129]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[142]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[111]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[13]

Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[143]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[144]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[145]
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[146]
Cepharanthine	DM9Y5JB	N. A.	N. A.	Approved	[147]
Itraconazole	DMCR1MV	Aspergillosis	1F20	Approved	[148]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[149]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[150]
Trifluoperazine	DMKBYWI	Anxiety		Approved	[151]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[149]

Drug(s) Affected By Dynamin-1-like protein (DNM1L)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[152]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[153]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[154]
Efavirenz	DMC0GSJ	Human immunodeficiency virus infection	1C62	Approved	[155]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[156]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[157]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[158]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[25]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[159]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[160]

Drug(s) Affected By Nuclear receptor subfamily 1 group I member 2 (NR1I2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vidarabine	DM0N85H	Hepatosplenic T-cell lymphoma		Approved	[161]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[162]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[163]
Secobarbital	DM14RF5	Epilepsy	8A60-8A68	Approved	[164]
Etidronic acid	DM1XHYJ	Bone Paget disease		Approved	[161]
Tiaprofenic acid	DM23D7J	Osteoarthritis	FA00-FA05	Approved	[161]
Bromperidol	DM24XYQ	Schizophrenia	6A20	Approved	[161]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[165]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[166]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[167]

Drug(s) Affected By ATP-binding cassette sub-family C member 6 (ABCC6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Benzbromarone	DMC3YUA	Gout	FA25	Approved	[21]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[169]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[174]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[178]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[171]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[179]
Adenosine triphosphate	DM79F6G	Malnutrition	5B50-5B71	Approved	[180]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[172]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[173]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[174]

Drug(s) Affected By Metalloproteinase inhibitor 1 (TIMP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pentoxifylline	DMU3DNC	Alcoholic hepatitis	DB94.1	Approved	[181]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[182]
Selenium	DM25CGV	N. A.	N. A.	Approved	[183]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[26]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[184]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[185]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[186]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[187]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[188]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[189]

Drug(s) Affected By Protein c-Fos (FOS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[190]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[191]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[192]
Acebutolol	DM0TI4U	Hypertension	BA00-BA04	Approved	[193]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[194]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[195]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[196]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[197]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[198]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[199]

Drug(s) Affected By Natriuretic peptides A (NPPA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[200]
Naloxone	DM3FXMA	Narcotic depression	6A7Z	Approved	[201]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[202]
Cilazapril	DM4V6JA	Congestive heart failure	BD10	Approved	[203]
Lisinopril	DMUOK4C	Chronic heart failure	BD1Z	Approved	[204]
Irbesartan	DMTP1DC	Diabetic kidney disease	GB61.Z	Approved	[205]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[206]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[173]
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[207]
Carvedilol	DMHTEAO	Chronic heart failure	BD1Z	Approved	[208]

Drug(s) Affected By Platelet basic protein (PPBP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[209]
Nortriptyline	DM4KDYJ	Depression	6A70-6A7Z	Approved	[210]
Paroxetine	DM5PVQE	Anxiety disorder	6B00-6B0Z	Approved	[210]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[211]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[212]
Amlodipine	DMBDAZV	Angina pectoris	BA40	Approved	[213]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[173]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[214]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[215]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[216]

Drug(s) Affected By Phosphatidylcholine translocator ABCB4 (ABCB4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[217]
Methysergide	DM1EF73	Migraine	8A80	Approved	[218]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[219]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[220]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[218]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[169]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[185]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[221]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[222]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[170]

Drug(s) Affected By Potassium voltage-gated channel subfamily A member 3 (KCNA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[223]
Reserpine	DM6VM38	Hypertension	BA00-BA04	Approved	[224]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[173]
Econazole	DMFSWGH	Cutaneous candidiasis	1F23.14	Approved	[224]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[223]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[225]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[226]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[227]
Sulforaphane	DMQY3L0	Skin disease	EA00-EM0Z	Investigative	[228]

Drug(s) Affected By Galanin peptides (GAL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[229]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[26]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[230]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[231]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[232]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[233]
Methazolamide	DM7J2TA	Glaucoma/ocular hypertension	9C61	Approved	[26]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[233]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[234]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[173]

Drug(s) Affected By Alpha-1D adrenergic receptor (ADRA1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alfuzosin	DMZVMKF	Benign prostatic hyperplasia	GA90	Approved	[235]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[236]
Oxymetazoline	DM8ZXT6	Arrhythmia	BC9Z	Approved	[237]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[173]
Terbutaline	DMD4381	Asthma	CA23	Approved	[238]
Methoxamine	DMF5XQH	Hypertension	BA00-BA04	Approved	[237]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[20]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[238]
Norepinephrine	DMOUC09	Alopecia	ED70	Approved	[237]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[239]

Drug(s) Affected By MHC class II transactivator (CIITA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[240]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[190]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[241]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[173]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[214]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[240]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[242]
Azacitidine	DMTA5OE	Acute myelogenous leukaemia	2A41	Approved	[243]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[244]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[241]

Drug(s) Affected By Alpha-1A adrenergic receptor (ADRA1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tamsulosin	DM5QF9V	Benign prostatic hyperplasia	GA90	Approved	[245]
SILODOSIN	DMJSBT6	Benign prostatic hyperplasia	GA90	Approved	[236]
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[181]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[236]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[246]
Oxymetazoline	DM8ZXT6	Arrhythmia	BC9Z	Approved	[245]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[172]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[20]
Norepinephrine	DMOUC09	Alopecia	ED70	Approved	[235]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[247]

Drug(s) Affected By Alpha-1B adrenergic receptor (ADRA1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[236]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[230]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[248]
Oxymetazoline	DM8ZXT6	Arrhythmia	BC9Z	Approved	[249]
Terbutaline	DMD4381	Asthma	CA23	Approved	[238]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[20]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[238]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[250]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[225]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[251]

Drug(s) Affected By Multidrug and toxin extrusion protein 1 (SLC47A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pyrimethamine	DM5X7VY	Malaria	1F40-1F45	Approved	[252]
Cimetidine	DMH61ZB	Acid-reflux disorder	DA22	Approved	[253]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[253]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[254]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[179]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[172]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[255]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[214]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[253]
Mebendazole	DMO14SG	Ascariasis	1F62	Approved	[256]

Drug(s) Affected By Potassium voltage-gated channel subfamily D member 3 (KCND3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[257]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[233]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[233]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[258]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[259]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[260]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[261]
phorbol 12-myristate 13-acetate	DMJWD62	Acute myeloid leukaemia	2A60	Phase 2	[262]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[263]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[264]

Drug(s) Affected By Voltage-dependent L-type calcium channel subunit alpha-1C (CACNA1C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[264]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[220]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[265]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[266]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[173]
Retigabine	DMGNYIH	Behcet disease	4A62	Approved	[267]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[268]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[225]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[260]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[269]

Drug(s) Affected By Sodium channel protein type 5 subunit alpha (SCN5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[181]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[270]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[271]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[272]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[273]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[274]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[265]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[266]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[275]
Retigabine	DMGNYIH	Behcet disease	4A62	Approved	[267]

Drug(s) Affected By Calcium-activated potassium channel subunit beta-1 (KCNMB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[276]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[277]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[260]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[278]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[279]

Drug(s) Affected By Beta-1 adrenergic receptor (ADRB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dobutamine	DMD1B8Z	Heart failure	BD10-BD13	Approved	[280]
Carvedilol	DMHTEAO	Chronic heart failure	BD1Z	Approved	[281]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[220]
Vortioxetine	DM6F1PU	Major depressive disorder	6A70.3	Approved	[282]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[173]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[276]
Labetalol	DMK8U72	Hypertension	BA00-BA04	Approved	[283]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[284]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[285]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[260]
Dobutamine	DMD1B8Z	Heart failure	BD10-BD13	Approved	[280]
Carvedilol	DMHTEAO	Chronic heart failure	BD1Z	Approved	[281]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[220]
Vortioxetine	DM6F1PU	Major depressive disorder	6A70.3	Approved	[282]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[173]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[276]
Labetalol	DMK8U72	Hypertension	BA00-BA04	Approved	[283]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[284]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[285]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[260]

Drug(s) Affected By Potassium voltage-gated channel subfamily E member 1 (KCNE1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[286]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[258]
Pentobarbital	DMFNH7L	Brain ischaemia	8B1Z	Approved	[287]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[181]
Diltiazem	DMAI7ZV	Angina pectoris	BA40	Approved	[181]
Sotalol	DML60TN	Sinus rhythm disorder	BC9Y	Approved	[181]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[181]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[181]
Atenolol	DMNKG1Z	Angina pectoris	BA40	Approved	[181]
Procainamide	DMNMXR8	Ventricular arrhythmias	BC71	Approved	[181]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)	TT729IR	CAC1G_HUMAN	Blocker	[4]
HUMAN two pore channel subtype 2 (TPC2)	TTHQJ2Y	TPC2_HUMAN	Blocker	[5]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance protein 3 (ABCB4)	DTZRMK5	MDR3_HUMAN	Substrate	[6]
Organic cation/carnitine transporter 1 (SLC22A4)	DT2EG60	S22A4_HUMAN	Substrate	[7]
Organic cation/carnitine transporter 2 (SLC22A5)	DT3HUVD	S22A5_HUMAN	Substrate	[8]
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[9]
Multidrug resistance-associated protein 1 (ABCC1)	DTSYQGK	MRP1_HUMAN	Substrate	[10]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[11]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[12]
Cytochrome P450 2E1 (CYP2E1)	DEVDYN7	CP2E1_HUMAN	Substrate	[13]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[14]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[15]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[16]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[17]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Substrate	[13]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[18]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[19]
Cytochrome P450 2C18 (CYP2C18)	DEZMWRE	CP2CI_HUMAN	Substrate	[13]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Alpha-1A adrenergic receptor (ADRA1A)	OTUIWCL5	ADA1A_HUMAN	Protein Interaction/Cellular Processes	[20]
Alpha-1B adrenergic receptor (ADRA1B)	OTSAYAFD	ADA1B_HUMAN	Protein Interaction/Cellular Processes	[20]
Alpha-1D adrenergic receptor (ADRA1D)	OTW2CD1O	ADA1D_HUMAN	Protein Interaction/Cellular Processes	[20]
ATP-binding cassette sub-family C member 6 (ABCC6)	OTZT0LKT	MRP6_HUMAN	Gene/Protein Processing	[21]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Gene/Protein Processing	[22]
Beta-1 adrenergic receptor (ADRB1)	OTQBWN4U	ADRB1_HUMAN	Drug Response	[23]
Calcium-activated potassium channel subunit beta-1 (KCNMB1)	OTO4KNJ4	KCMB1_HUMAN	Drug Response	[24]
Dynamin-1-like protein (DNM1L)	OTXK1Q1G	DNM1L_HUMAN	Post-Translational Modifications	[25]
Galanin peptides (GAL)	OTB3VPTO	GALA_HUMAN	Gene/Protein Processing	[26]
Metalloproteinase inhibitor 1 (TIMP1)	OTOXC51H	TIMP1_HUMAN	Gene/Protein Processing	[26]

References

• [1] Verapamil FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2406).
• [3] ClinicalTrials.gov (NCT04351763) Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms. U.S. National Institutes of Health.
• [4] Mechanism of tissue-selective drug action in the cardiovascular system. Mol Interv. 2005 Apr;5(2):84-93.
• [5] Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020 Mar 27;11(1):1620.
• [6] MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9.
• [7] Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73.
• [8] Genetic variations of the SLC22A5 gene in the Chinese and Indian populations of Singapore. Drug Metab Pharmacokinet. 2010;25(1):112-9.
• [9] Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
• [10] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [11] Improved expression and purification of human multidrug resistance protein MDR1 from baculovirus-infected insect cells. Protein Expr Purif. 2009 Jul;66(1):7-14.
• [12] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [13] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [14] Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
• [15] Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
• [16] Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
• [17] Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
• [18] Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
• [19] Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
• [20] Effects of quinidine and verapamil on human cardiovascular alpha1-adrenoceptors. Circulation. 1998 Apr 7;97(13):1227-30. doi: 10.1161/01.cir.97.13.1227.
• [21] Multidrug resistance protein-6 (MRP6) in human dermal fibroblasts. Comparison between cells from normal subjects and from Pseudoxanthoma elasticum patients. Matrix Biol. 2003 Nov;22(6):491-500. doi: 10.1016/j.matbio.2003.09.001.
• [22] Rapid induction of P-glycoprotein expression by high permeability compounds in colonic cells in vitro: a possible source of transporter mediated drug interactions?. Biochem Pharmacol. 2004 Aug 15;68(4):783-90. doi: 10.1016/j.bcp.2004.05.006.
• [23] A common 1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation. J Am Coll Cardiol. 2012 Jan 3;59(1):49-56. doi: 10.1016/j.jacc.2011.08.061.
• [24] KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenet Genomics. 2007 Sep;17(9):719-29. doi: 10.1097/FPC.0b013e32810f2e3c.
• [25] Low doses of BPF-induced hypertrophy in cardiomyocytes derived from human embryonic stem cells via disrupting the mitochondrial fission upon the interaction between ER and calcineurin A-DRP1 signaling pathway. Cell Biol Toxicol. 2022 Jun;38(3):409-426. doi: 10.1007/s10565-021-09615-y. Epub 2021 May 22.
• [26] Discovery of molecular mechanisms of neuroprotection using cell-based bioassays and oligonucleotide arrays. Physiol Genomics. 2002 Oct 29;11(2):45-52. doi: 10.1152/physiolgenomics.00064.2002.
• [27] Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions. J Neurosci. 2008 Nov 12;28(46):11959-69.
• [28] Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007 Apr;226(1-2):52-60.
• [29] Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32.
• [30] Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci. 2002 Jan 15;22(2):396-403.
• [31] Pfizer. Product Development Pipeline. March 31 2009.
• [32] The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742.
• [33] Discovery of potent T-type calcium channel blocker. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5740-3.
• [34] Synthesis and biological evaluation of novel T-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Jan 15;17(2):471-5.
• [35] The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer. 2005 Jul 11;93(1):89-97.
• [36] Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
• [37] Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
• [38] Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14.
• [39] Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
• [40] ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
• [41] Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab Dispos. 2008 Dec;36(12):2571-81.
• [42] Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology. 2010 Jun;58(7):1019-32.
• [43] Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
• [44] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [45] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [46] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [47] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [48] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [49] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [50] Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
• [51] Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
• [52] Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
• [53] Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
• [54] Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
• [55] Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
• [56] Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
• [57] Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
• [58] Pharmacokinetics and disposition of silodosin (KMD-3213)]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45.
• [59] Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84.
• [60] Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
• [61] Colistin is substrate of the carnitine/organic cation transporter 2 (OCTN2, SLC22A5). Drug Metab Dispos. 2017 Dec;45(12):1240-1244.
• [62] Novel organic cation transporter 2-mediated carnitine uptake in placental choriocarcinoma (BeWo) cells. J Pharmacol Exp Ther. 2005 Jan;312(1):192-8.
• [63] Mutations affecting GABAergic signaling in seizures and epilepsy. Pflugers Arch. 2010 Jul;460(2):505-23.
• [64] Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010 Feb 1;7(1):187-95.
• [65] Genetic deficiency of carnitine/organic cation transporter 2 (slc22a5) is associated with altered tissue distribution of its substrate pyrilamine in mice. Biopharm Drug Dispos. 2009 Dec;30(9):495-507.
• [66] Cloning and functional characterization of a novel up-regulator, cartregulin, of carnitine transporter, OCTN2. Arch Biochem Biophys. 2006 Aug 1;452(1):29-37.
• [67] OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. Cancer Res. 2017 Apr 15;77(8):2102-2111.
• [68] Spontaneous development of intestinal and colonic atrophy and inflammation in the carnitine-deficient jvs (OCTN2(-/-)) mice. Mol Genet Metab. 2007 Dec;92(4):315-24.
• [69] Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther. 2008 Mar;83(3):416-21.
• [70] Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4). Pharmacogenet Genomics. 2007 Sep;17(9):773-82.
• [71] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [72] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [73] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [74] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [75] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [76] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [77] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [78] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [79] Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metab Dispos. 2000 Sep;28(9):1043-50.
• [80] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [81] Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
• [82] Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
• [83] Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
• [84] PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
• [85] The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
• [86] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [87] Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
• [88] Ontogeny and sorafenib metabolism. Clin Cancer Res. 2012 Oct 15;18(20):5788-95.
• [89] Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
• [90] Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
• [91] Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
• [92] Drug Interactions Flockhart Table
• [93] Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
• [94] Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
• [95] Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
• [96] Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
• [97] 16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis. 1998 May;19(5):867-72.
• [98] Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
• [99] Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
• [100] Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
• [101] Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
• [102] A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
• [103] Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
• [104] Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
• [105] CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
• [106] Effects of nicotine on cytochrome P450 2A6 and 2E1 activities. Br J Clin Pharmacol. 2010 Feb;69(2):152-9.
• [107] The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
• [108] The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
• [109] Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers.
• [110] Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
• [111] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [112] Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
• [113] Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys. 1997 Feb 15;338(2):157-64.
• [114] Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996 Mar;9(2):365-73.
• [115] CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
• [116] Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001 Mar;29(3):242-51.
• [117] Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
• [118] Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
• [119] Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
• [120] Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
• [121] PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
• [122] Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87.
• [123] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [124] Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
• [125] Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
• [126] Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
• [127] New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
• [128] A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
• [129] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [130] In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol. 1996;50(3):209-15.
• [131] Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
• [132] Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
• [133] Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
• [134] Drugs that may have potential CYP2B6 interactions.
• [135] Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
• [136] Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
• [137] PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
• [138] Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
• [139] High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
• [140] Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
• [141] CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
• [142] Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
• [143] Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
• [144] Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
• [145] Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
• [146] Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
• [147] Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
• [148] Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
• [149] Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
• [150] Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
• [151] Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.
• [152] Tea polyphenols direct Bmal1-driven ameliorating of the redox imbalance and mitochondrial dysfunction in hepatocytes. Food Chem Toxicol. 2018 Dec;122:181-193.
• [153] Statin-triggered cell death in primary human lung mesenchymal cells involves p53-PUMA and release of Smac and Omi but not cytochrome c. Biochim Biophys Acta. 2010 Apr;1803(4):452-67. doi: 10.1016/j.bbamcr.2009.12.005. Epub 2010 Jan 4.
• [154] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [155] Lon protease: a novel mitochondrial matrix protein in the interconnection between drug-induced mitochondrial dysfunction and endoplasmic reticulum stress. Br J Pharmacol. 2017 Dec;174(23):4409-4429. doi: 10.1111/bph.14045. Epub 2017 Nov 7.
• [156] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [157] Protective effects of silibinin against ethanol- or acetaldehyde-caused damage in liver cell lines involve the repression of mitochondrial fission. Toxicol In Vitro. 2022 Apr;80:105330. doi: 10.1016/j.tiv.2022.105330. Epub 2022 Feb 11.
• [158] Increased mitochondrial ROS formation by acetaminophen in human hepatic cells is associated with gene expression changes suggesting disruption of the mitochondrial electron transport chain. Toxicol Lett. 2015 Apr 16;234(2):139-50.
• [159] Doxorubicin-induced mitophagy and mitochondrial damage is associated with dysregulation of the PINK1/parkin pathway. Toxicol In Vitro. 2018 Sep;51:1-10. doi: 10.1016/j.tiv.2018.05.001. Epub 2018 May 3.
• [160] Sumoylation of eukaryotic elongation factor 2 is vital for protein stability and anti-apoptotic activity in lung adenocarcinoma cells. Cancer Sci. 2011 Aug;102(8):1582-9. doi: 10.1111/j.1349-7006.2011.01975.x. Epub 2011 Jun 23.
• [161] Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
• [162] Induction of PXR-mediated metabolism by beta-carotene. Biochim Biophys Acta. 2005 May 30;1740(2):162-9. doi: 10.1016/j.bbadis.2004.11.013. Epub 2004 Dec 8.
• [163] Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR). Toxicol Appl Pharmacol. 2005 Dec 1;209(2):123-33. doi: 10.1016/j.taap.2005.03.015.
• [164] Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos. 2011 Feb;39(2):337-44. doi: 10.1124/dmd.110.035808. Epub 2010 Nov 10.
• [165] Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
• [166] Acetylated deoxycholic (DCA) and cholic (CA) acids are potent ligands of pregnane X (PXR) receptor. Toxicol Lett. 2017 Jan 4;265:86-96.
• [167] Stable cellular models of nuclear receptor PXR for high-throughput evaluation of small molecules. Toxicol In Vitro. 2018 Oct;52:222-234.
• [168] Clozapine-induced reduction of l-carnitine reabsorption via inhibition/down-regulation of renal carnitine/organic cation transporter 2 contributes to liver lipid metabolic disorder in mice. Toxicol Appl Pharmacol. 2019 Jan 15;363:47-56. doi: 10.1016/j.taap.2018.11.007. Epub 2018 Nov 19.
• [169] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [170] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [171] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [172] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [173] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [174] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [175] Multiple drug transporters mediate the placental transport of sulpiride. Arch Toxicol. 2017 Dec;91(12):3873-3884. doi: 10.1007/s00204-017-2008-8. Epub 2017 Jun 9.
• [176] Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs. Nephrol Dial Transplant. 2010 Feb;25(2):426-33. doi: 10.1093/ndt/gfp456. Epub 2009 Sep 7.
• [177] Inorganic arsenic as an endocrine disruptor: modulation of the glucocorticoid receptor pathway in placental cells via CpG methylation. Chem Res Toxicol. 2019 Mar 18;32(3):493-499.
• [178] Expression of the human ABCC6 gene is induced by retinoids through the retinoid X receptor. Biochem Biophys Res Commun. 2006 Dec 1;350(4):1082-7. doi: 10.1016/j.bbrc.2006.10.007. Epub 2006 Oct 10.
• [179] Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
• [180] Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6). J Biol Chem. 2002 May 10;277(19):16860-7.
• [181] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [182] Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J. 2012 Apr;26(4):1535-48. doi: 10.1096/fj.11-198184. Epub 2011 Dec 23.
• [183] Inhibition of invasion and induction of apoptosis by selenium in human malignant brain tumour cells in vitro. Int J Oncol. 2007 May;30(5):1263-71.
• [184] Dietary supplementation with the anti-tumour promoter quercetin: its effects on matrix metalloproteinase gene regulation. Mutat Res. 2001 Sep 1;480-481:269-76. doi: 10.1016/s0027-5107(01)00184-1.
• [185] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [186] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [187] Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species. J Cell Biochem. 2005 Aug 1;95(5):955-69. doi: 10.1002/jcb.20452.
• [188] Aspirin inhibits MMP-2 and MMP-9 expressions and activities through upregulation of PPARalpha/gamma and TIMP gene expressions in ox-LDL-stimulated macrophages derived from human monocytes. Pharmacology. 2009;83(1):18-25. doi: 10.1159/000166183. Epub 2008 Oct 30.
• [189] R(+)-methanandamide and other cannabinoids induce the expression of cyclooxygenase-2 and matrix metalloproteinases in human nonpigmented ciliary epithelial cells. J Pharmacol Exp Ther. 2006 Mar;316(3):1219-28.
• [190] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [191] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [192] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [193] Selection of drugs to test the specificity of the Tg.AC assay by screening for induction of the gadd153 promoter in vitro. Toxicol Sci. 2003 Aug;74(2):260-70. doi: 10.1093/toxsci/kfg113. Epub 2003 May 2.
• [194] Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
• [195] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [196] Methotrexate induces production of IL-1 and IL-6 in the monocytic cell line U937. Arthritis Res Ther. 2014 Jan 20;16(1):R17. doi: 10.1186/ar4444.
• [197] Simvastatin inhibits NOR-1 expression induced by hyperlipemia by interfering with CREB activation. Cardiovasc Res. 2005 Aug 1;67(2):333-41. doi: 10.1016/j.cardiores.2005.03.016. Epub 2005 Apr 21.
• [198] The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem. 2004 Jun 25;279(26):27008-16. doi: 10.1074/jbc.M403588200. Epub 2004 Apr 16.
• [199] Fluoxetine inhibits the extracellular signal regulated kinase pathway and suppresses growth of cancer cells. Cancer Biol Ther. 2008 Oct;7(10):1685-93. doi: 10.4161/cbt.7.10.6664. Epub 2008 Oct 22.
• [200] Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001 Apr;37(5):1228-33. doi: 10.1016/s0735-1097(01)01116-0.
• [201] Opioid peptides attenuate blood pressure increase in acute respiratory failure. Peptides. 2001 Apr;22(4):631-7. doi: 10.1016/s0196-9781(01)00373-4.
• [202] Atrial-like Engineered Heart Tissue: An In?Vitro Model of the Human Atrium. Stem Cell Reports. 2018 Dec 11;11(6):1378-1390. doi: 10.1016/j.stemcr.2018.10.008. Epub 2018 Nov 8.
• [203] Effects of angiotensin converting enzyme inhibitors and calcium antagonists on atrial natriuretic peptide release and action and on albumin excretion rate in hypertensive insulin-dependent diabetic patients. Am J Hypertens. 1992 Nov;5(11):837-46. doi: 10.1093/ajh/5.11.837.
• [204] Effects of lisinopril on cardiorespiratory, neuroendocrine, and renal function in patients with asymptomatic left ventricular dysfunction. Br Heart J. 1993 Jun;69(6):512-5. doi: 10.1136/hrt.69.6.512.
• [205] Plasma atrial natriuretic peptide in essential hypertension after treatment with irbesartan. Blood Press. 2002;11(2):91-4. doi: 10.1080/08037050211263.
• [206] 1,25-dihydroxyvitamin D inhibits human ANP gene promoter activity. Regul Pept. 2005 Jun 30;128(3):197-202. doi: 10.1016/j.regpep.2004.12.030.
• [207] Experimental studies on cortisol-induced hypertension in humans. J Hum Hypertens. 1995 Jun;9(6):395-9.
• [208] Effects of carvedilol on atrial natriuretic peptide, catecholamines, and hemodynamics in hypertension at rest and during exercise. J Cardiovasc Pharmacol. 1992;19 Suppl 1:S90-6. doi: 10.1097/00005344-199219001-00018.
• [209] Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation. 2003 Aug 26;108(8):939-44. doi: 10.1161/01.CIR.0000085163.21752.0A. Epub 2003 Aug 11.
• [210] Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol. 2000 Apr;20(2):137-40. doi: 10.1097/00004714-200004000-00004.
• [211] Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
• [212] Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
• [213] Platelet morphology and plasma indices of platelet activation in essential hypertension: effects of amlodipine-based antihypertensive therapy. Ann Med. 2004;36(7):552-7. doi: 10.1080/07853890410017386.
• [214] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [215] Cocaine activates platelets and increases the formation of circulating platelet containing microaggregates in humans. Heart. 2000 Jun;83(6):688-95. doi: 10.1136/heart.83.6.688.
• [216] Arsenic exposure from drinking water is associated with decreased gene expression and increased DNA methylation in peripheral blood. Toxicol Appl Pharmacol. 2017 Apr 15;321:57-66. doi: 10.1016/j.taap.2017.02.019. Epub 2017 Feb 24.
• [217] [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel]. Zhonghua Fu Chan Ke Za Zhi. 2007 Jun;42(6):412-6.
• [218] Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
• [219] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [220] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [221] Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
• [222] Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
• [223] A cell-based Rb(+)-flux assay of the Kv1.3 potassium channel. Assay Drug Dev Technol. 2007 Jun;5(3):373-80. doi: 10.1089/adt.2006.004.
• [224] Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels. Toxicol Appl Pharmacol. 2011 May 1;252(3):250-8. doi: 10.1016/j.taap.2011.02.016. Epub 2011 Feb 26.
• [225] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [226] BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011 Sep 16;146(6):904-17.
• [227] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [228] Sulforaphane-induced apoptosis in human leukemia HL-60 cells through extrinsic and intrinsic signal pathways and altering associated genes expression assayed by cDNA microarray. Environ Toxicol. 2017 Jan;32(1):311-328.
• [229] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [230] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [231] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [232] JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.
• [233] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [234] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [235] The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994 Apr;45(4):703-8.
• [236] Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004 Sep 1;63(4):662-72. doi: 10.1016/j.cardiores.2004.05.014.
• [237] Chromatography studies on bio-affinity of nine ligands of alpha1-adrenoceptor to alpha1D subtypes overexpressed in cell membrane. Sci China C Life Sci. 2004 Aug;47(4):376-81. doi: 10.1360/03yc0109.
• [238] Neuroendocrine mediators up-regulate alpha1b- and alpha1d-adrenergic receptor subtypes in human monocytes. J Neuroimmunol. 1999 Mar 1;95(1-2):165-73. doi: 10.1016/s0165-5728(99)00011-9.
• [239] Epigenetic regulation of human alpha1d-adrenergic receptor gene expression: a role for DNA methylation in Sp1-dependent regulation. FASEB J. 2007 Jul;21(9):1979-93. doi: 10.1096/fj.06-7118com. Epub 2007 Mar 23.
• [240] Induction of class II major histocompatibility complex expression in human multiple myeloma cells by retinoid. Haematologica. 2007 Jan;92(1):115-20.
• [241] Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. Chem Biol Interact. 2016 Aug 5;255:31-44.
• [242] Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
• [243] The effect of DNA methylation inhibitor 5-Aza-2'-deoxycytidine on human endometrial stromal cells. Hum Reprod. 2010 Nov;25(11):2859-69.
• [244] Effect of prenatal arsenic exposure on DNA methylation and leukocyte subpopulations in cord blood. Epigenetics. 2014 May;9(5):774-82. doi: 10.4161/epi.28153. Epub 2014 Feb 13.
• [245] Cell membrane chromatography competitive binding analysis for characterization of 1A adrenoreceptor binding interactions. Anal Bioanal Chem. 2011 Jul;400(10):3625-33. doi: 10.1007/s00216-011-5026-z. Epub 2011 May 5.
• [246] Adipogenic Effects and Gene Expression Profiling of Firemaster? 550 Components in Human Primary Preadipocytes. Environ Health Perspect. 2017 Sep 14;125(9):097013. doi: 10.1289/EHP1318.
• [247] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [248] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [249] Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39.
• [250] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [251] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [252] Interactions between Oroxylin A with the solute carrier transporters and ATP-binding cassette transporters: Drug transporters profile for this flavonoid. Chem Biol Interact. 2020 Jun 1;324:109097. doi: 10.1016/j.cbi.2020.109097. Epub 2020 Apr 16.
• [253] Molecular identification and functional characterization of rat multidrug and toxin extrusion type transporter 1 as an organic cation/H+ antiporter in the kidney. Drug Metab Dispos. 2006 Nov;34(11):1868-74. doi: 10.1124/dmd.106.010876. Epub 2006 Aug 23.
• [254] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [255] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [256] Mebendazole, an antiparasitic drug, inhibits drug transporters expression in preclinical model of gastric peritoneal carcinomatosis. Toxicol In Vitro. 2017 Sep;43:87-91. doi: 10.1016/j.tiv.2017.06.007. Epub 2017 Jun 9.
• [257] Establishment of ion channel and ABC transporter assays in 3D-cultured ReNcell VM on a 384-pillar plate for neurotoxicity potential. Toxicol In Vitro. 2022 Aug;82:105375. doi: 10.1016/j.tiv.2022.105375. Epub 2022 May 10.
• [258] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [259] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [260] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [261] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [262] Mechanism of alpha-adrenergic regulation of expressed hKv4.3 currents. Am J Physiol Heart Circ Physiol. 2001 Dec;281(6):H2518-27. doi: 10.1152/ajpheart.2001.281.6.H2518.
• [263] Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
• [264] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [265] Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55.
• [266] Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2016 Apr 1;296:42-53. doi: 10.1016/j.taap.2016.01.015. Epub 2016 Jan 25.
• [267] Modulation of the heart's electrical properties by the anticonvulsant drug retigabine. Toxicol Appl Pharmacol. 2017 Aug 15;329:309-317. doi: 10.1016/j.taap.2017.06.018. Epub 2017 Jun 20.
• [268] Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
• [269] Exposure to Insecticides Modifies Gene Expression and DNA Methylation in Hematopoietic Tissues In Vitro. Int J Mol Sci. 2023 Mar 26;24(7):6259. doi: 10.3390/ijms24076259.
• [270] Ethnic-Related Sodium Voltage-Gated Channel Subunit 5 Polymorphisms Shape the In Vitro Pharmacological Action of Amiodarone upon Na(v)1.5. Mol Pharmacol. 2021 Jun;99(6):448-459. doi: 10.1124/molpharm.120.000176. Epub 2021 Apr 6.
• [271] Flecainide test in Brugada syndrome: a reproducible but risky tool. Pacing Clin Electrophysiol. 2003 Jan;26(1P2):338-41. doi: 10.1046/j.1460-9592.2003.00045.x.
• [272] Inhibitory effects of cannabidiol on voltage-dependent sodium currents. J Biol Chem. 2018 Oct 26;293(43):16546-16558. doi: 10.1074/jbc.RA118.004929. Epub 2018 Sep 14.
• [273] Regulatory effects of non-steroidal anti-inflammatory drugs on cardiac ion channels Nav1.5 and Kv11.1. Chem Biol Interact. 2021 Apr 1;338:109425. doi: 10.1016/j.cbi.2021.109425. Epub 2021 Feb 19.
• [274] Quantitative proteomic analysis of HepG2 cells treated with quercetin suggests IQGAP1 involved in quercetin-induced regulation of cell proliferation and migration. OMICS. 2009 Apr;13(2):93-103. doi: 10.1089/omi.2008.0075.
• [275] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [276] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [277] Identification of transcriptional biomarkers induced by SERMS in human endometrial cells using multivariate analysis of DNA microarrays. Biomarkers. 2004 Nov-Dec;9(6):447-60.
• [278] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [279] Comparison of transcriptome expression alterations by chronic exposure to low-dose bisphenol A in different subtypes of breast cancer cells. Toxicol Appl Pharmacol. 2019 Dec 15;385:114814. doi: 10.1016/j.taap.2019.114814. Epub 2019 Nov 9.
• [280] The Arg389Gly 1-adrenoceptor gene polymorphism influences the acute effects of -adrenoceptor blockade on contractility in the human heart. Clin Res Cardiol. 2011 Aug;100(8):641-7. doi: 10.1007/s00392-011-0288-1. Epub 2011 Feb 11.
• [281] Agonist actions of "beta-blockers" provide evidence for two agonist activation sites or conformations of the human beta1-adrenoceptor. Mol Pharmacol. 2003 Jun;63(6):1312-21. doi: 10.1124/mol.63.6.1312.
• [282] Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. doi: 10.1021/jm101459g. Epub 2011 Apr 12.
• [283] Preclinical pharmacologic properties of dilevalol, an antihypertensive agent possessing selective beta 2 agonist-mediated vasodilation and beta antagonism. Am J Cardiol. 1989 Jun 5;63(19):3I-6I. doi: 10.1016/0002-9149(89)90120-3.
• [284] Effects of chronic amiodarone treatment on human myocardial beta adrenoceptor density and adenylate cyclase response. Cardiovasc Res. 1991 Jun;25(6):503-9. doi: 10.1093/cvr/25.6.503.
• [285] Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin. J Soc Gynecol Investig. 2005 Oct;12(7):e55-67.
• [286] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [287] Inhibition of cardiac potassium currents by pentobarbital. Naunyn Schmiedebergs Arch Pharmacol. 2002 Jan;365(1):29-37. doi: 10.1007/s00210-001-0490-1. Epub 2001 Nov 8.